|Articles|March 8, 2022
- Pharmaceutical Executive-03-01-2022
- Volume 42
- Issue 3
Pharmaceutical Executive, March 2022 Issue (PDF)
Advertisement
Articles in this issue
over 4 years ago
Pressed Into Action: Measuring Pharma’s Reputation Reversalover 4 years ago
Biopharma in 2021: Big Gains, Volatile Valuesover 4 years ago
The Resilience of R&D: Pharma Posted Record Output in 2021over 4 years ago
New Age of Psychedelicsover 4 years ago
Roads Less Traveledover 4 years ago
Biopharma Stocks, M&A Sputter Amid More Headwindsover 4 years ago
Pandemic Accelerates CTV Ascent: How Pharma Can Benefitover 4 years ago
The Human Factor in Data Security Breachesover 4 years ago
Tapping the Surge in Useful Contingent Labor MarketAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Lipfendra to reduce LDL-C in Adults with Hypercholesterolemia
2
Jasper Therapeutics to Acquire Kira Pharmaceuticals in $132 Million Merger Agreement
3
Pharmaceutical Executive Daily: FDA Approves Lipfendra
4
From Dr. Google to Dr. Claude: Why the Most Important Patient Support Innovation Is Still Human Connection
5